A leader in high-volume vaccine trials and research involving hard-to-reach patients
The majority of the world’s leading Sponsors and CROs have made Meridian a preferred partner for their traditional and next-generation infectious disease programs. This is because Meridian provides a broad North American footprint to support rapid enrollment, even for seasonal studies involving specific cohorts (e.g., seniors, pediatrics, healthy).
As the largest member of the Platinum Research Network, Meridian provides access to more than 40 million patients globally. Meridian also offers a flexible clinical infrastructure to accommodate new technologies and novel approaches.
Meridian principal investigators have had their research published in prestigious industry journals, including Vaccine. These investigators are also sought after by Sponsors and CROs to provide counsel for vaccine-related protocol development.
Across all major and emerging indications, including anti-infectives and immunologics, Meridian supports research programs for drugs, medical devices, diagnostics, and combination products.
- C. difficile
- Cytomegalovirus (CMV)
- Dengue fever
- H1N1 influenza
- H5N1 influenza
- Human Metapneumovirus (hMPV)
- Human papillomavirus (HPV)
- Influenza, including pediatric, geriatric, and off-season
- Japanese encephalitis
- Lyme disease
- Pediatric meningitis
- Pediatric influenza
- Respiratory syncytial virus (RSV), including maternal and pediatric
- SARS-CoV-2 (the coronavirus that causes COVID-19)
- Type 3 (PIV3)/RSV combo
- West Nile virus
- Zika virus
Cumulative vaccine trial enrollment by year
Types of vaccine trials conducted
Government-funded research experience
In-house QA and superb regulatory track record
First-in-human trial experience
Trial results featured in prestigious publications, including Vaccine